| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1094 | |
| Phytochemical name or plant extracts | Dioscin | |
| PMID | 26682631 | |
| Literature evidence | We propose that DS has potential to be used as an anti-invasive agent in breast cancer. | |
| IUPAC name | (2S,3R,4R,5R,6S)-2-[(2R,3S,4S,5R,6R)-4-hydroxy-2-(hydroxymethyl)-6-[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxy-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol | |
| Phytochemicals’ class or type of plant extracts | Steroidal saponin | |
| Source of phytochemicals or plant Extracts | Dioscorea villosa | |
| Geographical availability | Alabama, Arkansas, Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, New Jersey, New York, North Carolina, Ohio, Oklahoma, Ontario, Pennsylvania, Rhode I., South Carolina, Tennessee, Texas, Vermont, Virginia, West Virginia, Wisconsin | |
| Plant parts | Root | |
| Other cancers | Breast cancer | |
| Target gene or protein | GATA3, DNMT3A, TET2, TET3, ZFPM2 , E-cad, TET1, VIM, MMP9, Bcl-2, cIAP-1, Mcl-1 | |
| Gene or Protein evidence | GATA3 expression was enhanced by DS (5.76 μM) in MDA-MB-231 cells. DS (5.76 μM)-treated MDA-MB-231 cells exhibited the morphological characteristic of epithelial-like cells, mRNA expression of DNMT3A, TET2, TET3, ZFPM2 and E-cad were increased while TET1, VIM and MMP9 were decreased. Taken together, our results demonstrate that dioscin-induced cell death was mediated via AIF-facilitating caspase-independent pathway as well as down-regulating anti-apoptotic proteins such as Bcl-2, cIAP-1, and Mcl-1 in breast cancer cells. | |
| Target pathways | GATA3-dependent pathway | |
| IC50 | At 24h, 72h: 13.70 µM, 3.85 µM against MCF-7 6.77 µM, 2.07 µM against MDA-MB-231 | |
| Potency | We propose that DS has potential to be used as an anti-invasive agent in breast cancer. | |
| Cell line/ mice model | MCF-7, MDA-MB-231, T47D | |
| Additional information | DS is also used as traditional medicine in the treatment of hyper-cholesterolemia, hyperglycemia, hypertriacylglycerolemia and diabetes. | |
| PubChem ID | 119245 | |
| Additional PMIDs | 31611520 16766007 24771279 26682631 16797625 27331101 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:318778-1 | |
| Safety | Moreover, DS was found to have no subchronic toxicity in Sprague Dawley female rats with an oral administration of 300 mg/kg for three months. |